Linked Life Data

1284198

Source:http://linkedlifedata.com/resource/pubmed/id/1284198

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1284198rdf:typepubmed:Citationlld:pubmed
pubmed-article:1284198lifeskim:mentionsumls-concept:C0302592lld:lifeskim
pubmed-article:1284198lifeskim:mentionsumls-concept:C0027651lld:lifeskim
pubmed-article:1284198lifeskim:mentionsumls-concept:C0003320lld:lifeskim
pubmed-article:1284198lifeskim:mentionsumls-concept:C0021770lld:lifeskim
pubmed-article:1284198lifeskim:mentionsumls-concept:C0332281lld:lifeskim
pubmed-article:1284198lifeskim:mentionsumls-concept:C1306673lld:lifeskim
pubmed-article:1284198lifeskim:mentionsumls-concept:C0021044lld:lifeskim
pubmed-article:1284198lifeskim:mentionsumls-concept:C0220901lld:lifeskim
pubmed-article:1284198lifeskim:mentionsumls-concept:C1522609lld:lifeskim
pubmed-article:1284198lifeskim:mentionsumls-concept:C1554112lld:lifeskim
pubmed-article:1284198pubmed:issue6Blld:pubmed
pubmed-article:1284198pubmed:dateCreated1993-4-9lld:pubmed
pubmed-article:1284198pubmed:abstractTextThe prediction of prognosis in cervical carcinomas solely by histological examination is doubtful. Our study was undertaken to evaluate whether Cytokeratin 5D3, Cytokeratin high molecular weight (HMW), Cytokeratin AE1/AE3, Carcinoembryonic Antigen (CEA) and CA 19.9 could have a prognostic value in primarily irradiated stage FIGO III cervical cancer. We investigated 45 pretreatment punch biopsies of cervical cancer stage FIGO III. All patients underwent a combined standardised primary irradiation treatment. In the cases with expression of Cytokeratin AE1/AE3 survival was significantly better than in cases without expression. The expression of CEA also had a significantly positive effect on survival. The best prognosis was found in cases with coexpression of AE1/AE3 and CEA (Wilcoxon p = 0.006, log-Rank p = 0.03). The other investigated tumor associated antigen and intermediate filaments did not correlate with survival. The application of Cytokeratin AE1/AE3 and CEA allows a prediction of prognosis in patients with stage FIGO III cervical cancer undergoing irradiation treatment.lld:pubmed
pubmed-article:1284198pubmed:languageenglld:pubmed
pubmed-article:1284198pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1284198pubmed:citationSubsetIMlld:pubmed
pubmed-article:1284198pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1284198pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1284198pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1284198pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1284198pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1284198pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1284198pubmed:statusMEDLINElld:pubmed
pubmed-article:1284198pubmed:issn0250-7005lld:pubmed
pubmed-article:1284198pubmed:authorpubmed-author:SchneiderBBlld:pubmed
pubmed-article:1284198pubmed:authorpubmed-author:BreiteneckerG...lld:pubmed
pubmed-article:1284198pubmed:authorpubmed-author:DanihelLLlld:pubmed
pubmed-article:1284198pubmed:authorpubmed-author:GitschGGlld:pubmed
pubmed-article:1284198pubmed:authorpubmed-author:KainzCClld:pubmed
pubmed-article:1284198pubmed:authorpubmed-author:KoelblHHlld:pubmed
pubmed-article:1284198pubmed:authorpubmed-author:KohlbergerPPlld:pubmed
pubmed-article:1284198pubmed:issnTypePrintlld:pubmed
pubmed-article:1284198pubmed:volume12lld:pubmed
pubmed-article:1284198pubmed:ownerNLMlld:pubmed
pubmed-article:1284198pubmed:authorsCompleteYlld:pubmed
pubmed-article:1284198pubmed:pagination2017-9lld:pubmed
pubmed-article:1284198pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1284198pubmed:meshHeadingpubmed-meshheading:1284198-...lld:pubmed
pubmed-article:1284198pubmed:meshHeadingpubmed-meshheading:1284198-...lld:pubmed
pubmed-article:1284198pubmed:meshHeadingpubmed-meshheading:1284198-...lld:pubmed
pubmed-article:1284198pubmed:meshHeadingpubmed-meshheading:1284198-...lld:pubmed
pubmed-article:1284198pubmed:meshHeadingpubmed-meshheading:1284198-...lld:pubmed
pubmed-article:1284198pubmed:meshHeadingpubmed-meshheading:1284198-...lld:pubmed
pubmed-article:1284198pubmed:meshHeadingpubmed-meshheading:1284198-...lld:pubmed
pubmed-article:1284198pubmed:meshHeadingpubmed-meshheading:1284198-...lld:pubmed
pubmed-article:1284198pubmed:meshHeadingpubmed-meshheading:1284198-...lld:pubmed
pubmed-article:1284198pubmed:meshHeadingpubmed-meshheading:1284198-...lld:pubmed
pubmed-article:1284198pubmed:meshHeadingpubmed-meshheading:1284198-...lld:pubmed
pubmed-article:1284198pubmed:meshHeadingpubmed-meshheading:1284198-...lld:pubmed
pubmed-article:1284198pubmed:meshHeadingpubmed-meshheading:1284198-...lld:pubmed
pubmed-article:1284198pubmed:meshHeadingpubmed-meshheading:1284198-...lld:pubmed
pubmed-article:1284198pubmed:meshHeadingpubmed-meshheading:1284198-...lld:pubmed
pubmed-article:1284198pubmed:meshHeadingpubmed-meshheading:1284198-...lld:pubmed
pubmed-article:1284198pubmed:meshHeadingpubmed-meshheading:1284198-...lld:pubmed
pubmed-article:1284198pubmed:articleTitleImmunohistochemistry in stage FIGO III cervical cancer: prognostic value of tumor associated antigens and intermediate filaments.lld:pubmed
pubmed-article:1284198pubmed:affiliationII. Department of Obstetrics and Gynecology, University of Vienna, Austria.lld:pubmed
pubmed-article:1284198pubmed:publicationTypeJournal Articlelld:pubmed